Kelley Lauren Coffman, MD, on Key Takeaways from a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs
The hospitalist at Memorial Sloan Kettering Cancer Center discussed what she believes is most important for practicing oncologists to understand about a study of 177Lu-DOTATATE in well-differentiated, high-grade neuroendocrine tumors.
In a study presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, investigators evaluated responses and outcomes for patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera).
Overall, the investigators observed a meaningful disease control rate of 69% during treatment with 177Lu-DOTATATE. Moreover, over half of patients received all 4 cycles of treatment, with treatment-related toxicities largely consisting of bone-marrow related events.
In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, highlighted what she believes is most important for practicing oncologists to know about this study.
Transcription:
One important takeaway is that this therapy is available. It’s new. It’s a different type of therapy that’s generally used in neuroendocrine tumors. It is approved for [patients with] neuroendocrine tumors who have advanced metastatic analogues. And even in our patient population with higher-grade tumors, there can be benefit.
Reference:
Coffman KL, Bodei L, Le T, et al. Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE. J Clin Oncol. 2021;39(suppl 3). Abstract #: 368.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
